Home/Pipeline/BNT312 (GEN1053)

BNT312 (GEN1053)

Advanced solid tumors

Phase 1/2ActiveN/A

Key Facts

Indication

Advanced solid tumors

Phase

Phase 1/2

Status

Active

Company

BioNTech

About BioNTech

BioNTech SE is a pioneering German biotechnology company founded in 2008 with a mission to translate immunological science into life-saving immunotherapies and vaccines. Its historic achievement was the co-development and global commercialization of the first approved mRNA-based COVID-19 vaccine, Comirnaty, with Pfizer, which validated its core platform and provided substantial financial and operational resources. The company is now strategically deploying its validated mRNA technology, alongside complementary modalities like bispecific antibodies, to build a deep and diversified oncology pipeline while advancing next-generation vaccines for infectious diseases.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases

Other Advanced solid tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
M8891	Merck KGaA	Phase 1/2	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BP1001-A	Bio-Path Holdings	Phase 1	Active
FS222	F-star Therapeutics	Phase 1	Active (status post-acquisition)
FS120	F-star Therapeutics	Phase 1	Active (status post-acquisition)
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active